Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ZOM Stock Forecast 2026-2027
$0.06
Current Price
$95.35M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ZOM Price Targets
+354.5%
To High Target of $0.25
+354.5%
To Median Target of $0.25
+354.5%
To Low Target of $0.25
ZOM Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
0.0%
1 Year Change
0.0%
Year-to-Date Change
-71.8%
From 52W High of $0.20
+264.2%
From 52W Low of $0.02
📊 TOP ANALYST CALLS
Did ZOM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Zomedica is one of their latest high-conviction picks.
Latest ZOM Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, ZOM has a bullish consensus with a median price target of $0.25 (ranging from $0.25 to $0.25). The overall analyst rating is N/A (N/A/10). Currently trading at $0.06, the median forecast implies a 354.5% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZOM Analyst Ratings
1
Buy
0
Hold
0
Sell
ZOM Price Target Range
Low
$0.25
Average
$0.25
High
$0.25
Current: $0.06
Latest ZOM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZOM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 6, 2023 | Dawson James | Jason Kolbert | Buy | Initiates | $6.00 |
| Nov 16, 2020 | HC Wainwright & Co. | Buy | Maintains | $0.30 | |
| Jun 17, 2020 | HC Wainwright & Co. | Buy | Maintains | $0.50 |
Zomedica Corp. (ZOM) Competitors
The following stocks are similar to Zomedica based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Zomedica Corp. (ZOM) Financial Data
Valuation Metrics
Market Cap
$95.35M
Enterprise Value
$20.55M
P/E Ratio
N/A
PEG Ratio
N/A
Price/Sales
3.6x
Growth & Margins
Revenue Growth (YoY)
+10.2%
Gross Margin
+70.3%
Operating Margin
-106.3%
Net Margin
-232.7%
EPS Growth
+7.6%
Financial Health
Cash/Price Ratio
+141.8%
Current Ratio
10.8x
Debt/Equity
1.0x
ROE
-26.8%
ROA
-9.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Zomedica Corp. (ZOM) Business Model
About Zomedica Corp.
What They Do
Develops veterinary health products for companion animals.
Business Model
Zomedica Corp. generates revenue by developing and selling innovative diagnostic and therapeutic products aimed at addressing the needs of clinical veterinarians. Their offerings include advanced diagnostic platforms and therapeutic devices that improve animal health and wellness, which are marketed through collaborations and partnerships within the veterinary sector.
Additional Information
The company has established strategic collaboration agreements with Celsee, Inc. and Seraph Biosciences, Inc. to enhance its product offerings, including liquid biopsy assays for cancer detection and a novel pathogen detection system. Zomedica was previously known as Zomedica Pharmaceuticals Corp. and rebranded in October 2020, with its headquarters located in Ann Arbor, Michigan.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
144
CEO
Mr. Larry C. Heaton II
Country
United States
IPO Year
2017
Website
www.zomedica.comZomedica Corp. (ZOM) Latest News & Analysis
Latest News
Quick Summary
NYSE American is commencing delisting proceedings for Zomedica Corp. (ZOM) due to unsuitability under its listing standards, with immediate suspension of trading.
Why It Matters
Zomedica Corp.'s imminent delisting signals a loss of investor confidence and may lead to a decline in share value, impacting liquidity and future financing opportunities.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zomedica's shares will be delisted from NYSE American due to low prices and will start trading on OTCQB under the ticker symbol "ZOMDF" on March 5, 2025.
Why It Matters
Zomedica's delisting from NYSE American and shift to OTCQB can signal financial instability, impacting liquidity and investor confidence, potentially leading to increased volatility in share price.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Zomedica Corp. will hold a conference call on March 13, 2025, at 4:30 p.m. ET to review its Q4 and full-year 2024 operational and financial results.
Why It Matters
Zomedica's upcoming conference call will provide insights into its financial performance and operational updates, which could impact stock valuation and investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Zomedica Corp. has relocated its corporate headquarters to a more efficient facility in Ann Arbor, MI, reducing overhead costs by over $200,000 annually, supporting growth initiatives.
Why It Matters
Zomedica's relocation enhances operational efficiency and significantly cuts overhead costs, potentially improving profitability and attracting investor interest in its growth trajectory.
Source: Accesswire
Market Sentiment:
Neutral
Zomedica Launches the TRUFORMA(R) Enhanced Endogenous ACTH Assay to aid in Equine PPID Diagnosis
1 year ago
Quick Summary
Zomedica Corp. announced an update to its eACTH assay for equine plasma on the TRUFORMA biosensor, now the only point-of-care test for measuring eACTH in horses since its launch in September 2024.
Why It Matters
Zomedica's eACTH assay enhances its competitive edge in veterinary diagnostics, potentially increasing market share and revenues, which could boost investor confidence and stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Zomedica Corp. (NYSE American: ZOM) has secured a license agreement with Cresilon, Inc. to exclusively market Vetigel® hemostatic gel in the U.S., enhancing its veterinary product portfolio.
Why It Matters
Zomedica’s exclusive license for Vetigel® enhances its product lineup, potentially increasing revenue and market share in veterinary care, which could positively impact stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About ZOM Stock
What is Zomedica Corp.'s (ZOM) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Zomedica Corp. (ZOM) has a median price target of $0.25. The highest price target is $0.25 and the lowest is $0.25.
Is ZOM stock a good investment in 2027?
According to current analyst ratings, ZOM has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ZOM stock?
Wall Street analysts predict ZOM stock could reach $0.25 in the next 12 months. This represents a 354.5% increase from the current price of $0.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Zomedica Corp.'s business model?
Zomedica Corp. generates revenue by developing and selling innovative diagnostic and therapeutic products aimed at addressing the needs of clinical veterinarians. Their offerings include advanced diagnostic platforms and therapeutic devices that improve animal health and wellness, which are marketed through collaborations and partnerships within the veterinary sector.
What is the highest forecasted price for ZOM Zomedica Corp.?
The highest price target for ZOM is $0.25 from at , which represents a 354.5% increase from the current price of $0.06.
What is the lowest forecasted price for ZOM Zomedica Corp.?
The lowest price target for ZOM is $0.25 from at , which represents a 354.5% increase from the current price of $0.06.
What is the overall ZOM consensus from analysts for Zomedica Corp.?
The overall analyst consensus for ZOM is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $0.25.
How accurate are ZOM stock price projections?
Stock price projections, including those for Zomedica Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2026 6:24 PM UTC